Cartesian Therapeutics (RNAC) EBT Margin Growth (3y) (2018 - 2026)
Powered by 
Analysis
Cartesian Therapeutics (RNAC) EBT Margin Growth (3y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -484.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 132.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 6,691.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -2,054.00 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8,006.00 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 9,980.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -5,319.00 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 31,363.00 |
| 10 | Cartesian Therapeutics | 271.98 Mn | 271.98 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -3.23 Mn |
| Dec 31, 2025 | -820,349.00 |
| Sep 30, 2025 | -427,848.00 |
| Jun 30, 2025 | -676,655.00 |
| Mar 31, 2025 | -183,638.00 |
| Dec 31, 2024 | 315,721.00 |
| Sep 30, 2024 | -386,803.00 |
| Jun 30, 2024 | 4,602.00 |
| Mar 31, 2024 | -13,741.00 |
| Dec 31, 2023 | -224,987.00 |
| Sep 30, 2023 | 7,199.00 |
| Dec 31, 2022 | 22,541.00 |
| Jun 30, 2022 | 12.80 Mn |
| Mar 31, 2022 | 12.25 Mn |
| Dec 31, 2021 | 166,626.00 |
| Dec 31, 2020 | 11.40 Mn |
| Sep 30, 2020 | 5.15 Mn |
| Dec 31, 2019 | 28,814.00 |
| Jun 30, 2019 | -12.76 Mn |
| Mar 31, 2019 | -12.22 Mn |